<DOC>
	<DOC>NCT01005004</DOC>
	<brief_summary>The purpose of this study is to determine the safety and preliminary effectiveness of human central nervous system stem cells (HuCNS-SCÂ®) transplantation in patients with Connatal Pelizaeus-Merzbacher Disease (PMD).</brief_summary>
	<brief_title>Study of Human Central Nervous System (CNS) Stem Cells Transplantation in Pelizaeus-Merzbacher Disease (PMD) Subjects</brief_title>
	<detailed_description>Enrolled subjects will be transplanted with HuCNS-SC cells into the brain and will receive immunosuppression for nine months. The study observation period is for one year after transplant surgery. Thereafter, subjects will be enrolled in a long-term observational follow-up study for four years.</detailed_description>
	<mesh_term>Pelizaeus-Merzbacher Disease</mesh_term>
	<criteria>Confirmed clinical diagnosis of connatal PMD Molecular genetic confirmation of mutation in the proteolipid protein 1 (PLP1) gene MRI consistent with PMD as interpreted by a qualified neuroradiologist Other significant congenital brain abnormality not related to PMD Previous participation in gene transfer or cell transplant trial Presence of neurological signs and symptoms not consistent with PMD Current or prior malignancy Prior organ, tissue or bone marrow transplant</criteria>
	<gender>Male</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>PMD</keyword>
	<keyword>stem cells</keyword>
	<keyword>Pelizaeus-Merzbacher Disease</keyword>
	<keyword>human stem cells</keyword>
	<keyword>central nervous system stem cells</keyword>
</DOC>